EURASIAN EXPERIMENT JOURNAL OF PUBLIC HEALTH (EEJPH)

ISSN: 2992-4081 ©EEJPH Publications

Volume 7 Issue 1 2025

Adaptive Immunity in Response to Chronic Infections: A Mini Review

Kungu Erisa

Department of Pharmacognosy Kampala International University Uganda

Email: erisa.kungu@studwc.kiu.ac.ug

ABSTRACT

Chronic infections present a persistent challenge to the adaptive immune system, requiring prolonged immune responses that balance pathogen control with immune regulation. Unlike acute infections, chronic infections such as HIV, tuberculosis (TB), and hepatitis B virus (HBV) persist over time, leading to a complex immune response that can ultimately result in immune exhaustion and diminished efficacy. Adaptive immunity, driven by T and B cells, plays a critical role in targeting infected cells and generating immunological memory. However, pathogens in chronic infections employ a range of evasion strategies, including immune checkpoint manipulation, antigenic variation, and latency, to evade detection and maintain infection. Prolonged antigen exposure can exhaust immune cells, reducing their functional capacity and complicating pathogen control. Immunotherapeutic strategies, including immune checkpoint inhibitors, therapeutic vaccines, and adoptive cell transfer, aim to reinvigorate the adaptive immune system and improve its ability to combat persistent infections. These approaches are particularly promising for enhancing T and B cell responses in individuals with weakened immunity due to chronic infections. This review examines the adaptive immune mechanisms involved in chronic infections, the impact of immune exhaustion on disease progression, and emerging therapeutic strategies to bolster immune function.

Keywords: adaptive immunity, chronic infections, T cells, immune exhaustion, pathogen evasion, immunotherapy

INTRODUCTION

The adaptive immune system is essential for recognizing and responding to diverse pathogens, including bacteria, viruses, and parasites [1-4]. While acute infections trigger a rapid and robust immune response that clears the pathogen, chronic infections present a unique challenge, as the pathogen persists for extended periods, often months to years [5-9]. Chronic infections, including human immunodeficiency virus (HIV), hepatitis B virus (HBV), and Mycobacterium tuberculosis (TB), create complex immune dynamics [3]. The adaptive immune system relies on T and B cells to develop highly specific responses through the recognition of antigens, which ideally leads to pathogen clearance and immunological memory. However, chronic infections drive persistent antigenic stimulation that can exhaust the immune response, compromising the efficiency of T and B cells and potentially resulting in immune dysfunction [4]. Pathogens in chronic infections deploy various mechanisms to evade immune detection, including antigenic variation, latency, and immune checkpoint manipulation. For example, HIV and HBV persist by integrating into host genomes, while TB bacteria establish latency, allowing the pathogen to escape immune surveillance [5, 6]. These adaptations complicate the immune response, leading to the phenomenon of immune exhaustion, characterized by diminished T cell activity and reduced cytokine production, which limits the effectiveness of adaptive immunity. Understanding the adaptive immune response in chronic infections is critical to developing effective therapeutic interventions. Novel immunotherapeutic approaches—such as immune checkpoint inhibitors, therapeutic vaccines, and adoptive cell transfer—aim to reinvigorate exhausted immune cells and restore functionality [7]. This review provides an overview of the mechanisms driving adaptive immunity in chronic infections, explores the challenges posed by immune evasion and exhaustion, and highlights therapeutic strategies aimed at enhancing adaptive immune responses against chronic pathogens.

Mechanisms of Adaptive Immunity in Chronic Infections

Adaptive immunity, which involves T and B lymphocytes, is critical for mounting targeted responses against chronic infections and attempting to control pathogen persistence. Here, we explore the primary adaptive immune mechanisms involved in responding to chronic infections.

T Cell Responses

T cells play a central role in managing chronic infections through their ability to target and clear infected cells, as well as coordinate overall immune responses: Cytotoxic T Lymphocytes (CTLs): CD8+ T cells, also known as CTLs, recognize and kill infected cells. In chronic infections, the continuous exposure to antigens can lead to T cell exhaustion, a state characterized by reduced proliferation, diminished cytokine production, and decreased cytotoxicity [8]. Markers such as PD-1 and CTLA-4 are upregulated in exhausted T cells, reflecting their impaired functionality over time. Helper T Cells: CD4+ T cells support CTLs and B cells by secreting cytokines that amplify their responses. In chronic infections like HIV, the depletion of CD4+ T cells disrupts immune coordination, limiting the body's ability to effectively control the infection and contributing to immune dysregulation [9].

B Cell Responses and Antibody Production

B cells are essential to adaptive immunity due to their ability to produce antibodies that can neutralize or tag pathogens for destruction: Memory B Cells: In chronic infections, memory B cells are generated to maintain long-term antibody production. However, persistent immune activation in diseases like chronic hepatitis B can impair memory B cell function, compromising long-term immune responses [10, 11].

Antibody Maturation: Through somatic hypermutation and affinity maturation, B cells produce high-affinity antibodies that target pathogens more effectively [12, 13]. In chronic infections, these high-affinity antibodies play a crucial role in neutralizing pathogens and containing infection spread, though the constant antigen exposure can also disrupt this process.

Immune Memory and Chronic Infections

In chronic infections, immunological memory plays a dual role, contributing to both effective responses and challenges in controlling persistent pathogens. Memory T and B cells are essential for mounting rapid responses upon re-exposure to pathogens, yet continuous antigen presence in chronic infections can alter their functionality [14-19]:

Exhaustion of Memory Cells: Persistent antigen stimulation in chronic infections, such as HIV and HBV, can lead to the exhaustion of memory T cells. Exhausted memory cells exhibit reduced proliferation, impaired cytokine production, and decreased cytotoxic activity, limiting their effectiveness in controlling the infection [20-23].

Tissue-Resident Memory Cells: Some chronic infections, like tuberculosis (TB), involve tissue-resident memory T cells that provide localized immune surveillance in affected areas, such as the lungs [24-27]. These cells remain within specific tissues, allowing rapid response to pathogen reactivation while aiding in long-term containment.

Pathogen Evasion Mechanisms in Chronic Infections

Pathogens causing chronic infections employ a range of immune evasion strategies, enabling long-term persistence within the host: **Antigenic Variation:** Rapid mutation, as seen in HIV, leads to antigenic variation that helps pathogens evade recognition by antibodies and cytotoxic T lymphocytes (CTLs), complicating immune responses [28-31]. **Inhibitory Signals:** Chronic pathogens can induce immune checkpoint pathways, such as PD-1 and CTLA-4, on T cells, leading to immune suppression [18]. Elevated PD-1 expression is associated with T cell exhaustion in various chronic infections, diminishing T cell effectiveness.

Latency and Immune Privilege: Certain pathogens enter latent states or hide within immune-privileged sites, evading immune surveillance. For instance, herpesviruses can reside in neurons and avoid immune attack, reactivating under favorable conditions and causing recurrent infection [32-34].

Impact of Immune Exhaustion in Chronic Infections

Persistent infections can lead to immune exhaustion, a state in which T cells and other immune components lose their functionality due to prolonged activation. This exhaustion severely limits the adaptive immune system's ability to control chronic infections effectively, often contributing to disease progression:

Functional Decline of T Cells: In chronic infections like HBV and HIV, immune exhaustion results in a significant reduction in T cell effectiveness. Exhausted T cells lose their ability to produce key cytokines, exhibit reduced proliferation, and have diminished cytotoxic activity, impairing their capacity to clear infected cells and control the infection [20].

Biomarkers of Exhaustion: Exhausted T cells typically express high levels of inhibitory surface markers, such as PD-1, TIM-3, and LAG-3, which are associated with reduced immune activity [21]. These markers not only serve

as indicators of T cell exhaustion but also represent potential targets for immunotherapies that aim to rejuvenate T cell function in chronic infections.

Impact on Immune Memory: Continuous exposure to antigens in chronic infections can disrupt the formation of functional memory cells, further compromising the immune system's ability to respond to re-infection [22]. This impact on immune memory underscores the need for strategies that address exhaustion to improve immune resilience in chronic infection contexts. Understanding immune exhaustion's mechanisms and markers can guide therapeutic approaches, such as checkpoint inhibitors, to restore immune functionality and improve disease management in chronic infections.

Therapeutic Approaches to Enhance Adaptive Immunity in Chronic Infections

Therapies targeting adaptive immunity hold promise for managing chronic infections by revitalizing immune responses and overcoming immune exhaustion:

Immune Checkpoint Inhibitors

Immune checkpoint inhibitors, such as those targeting PD-1 and CTLA-4, aim to reinvigorate exhausted T cells, restoring their functionality [23]. Initially developed for cancer therapy, these inhibitors are now being explored in chronic infections, including HIV and hepatitis, to boost immune responses against persistent pathogens.

Therapeutic Vaccines

Therapeutic vaccines provide pathogen-specific antigens to stimulate immune memory, aiming to enhance T and B cell responses in individuals already infected [24]. By boosting the body's adaptive immunity, these vaccines may offer an additional tool to help control chronic infections.

Adoptive Cell Transfer

Adoptive cell transfer involves expanding pathogen-specific T cells outside the body and reinfusing them into patients. This approach provides a powerful, targeted immune response, especially beneficial for patients with significant immune suppression due to chronic infection.

Antiviral and Immunomodulatory Agents

Combining antiviral drugs with immunomodulators can reduce the pathogen burden, giving the immune system a better chance to mount a sustained adaptive response [25]. Immunomodulatory agents may also help restore immune balance, supporting the effectiveness of adaptive immunity in controlling the infection. These strategies highlight the potential of adaptive immunity-based therapies to transform chronic infection management and improve patient outcomes.

CONCLUSION

Adaptive immunity plays a pivotal role in controlling chronic infections but faces significant challenges due to persistent pathogen presence and immune evasion mechanisms. Understanding how T and B cells respond to chronic infections, along with the effects of immune exhaustion, is crucial for developing effective therapies. Advances in immunotherapies, checkpoint inhibitors, and therapeutic vaccines hold promise for enhancing adaptive immunity in patients with chronic infections. Future research should continue exploring innovative strategies to harness the adaptive immune system, offering hope for better management and eventual clearance of chronic infections.

REFERENCES

1. Zuniga EI, Macal M, Lewis GM, Harker JA. Innate and Adaptive Immune Regulation During Chronic Viral Infections. Annu Rev Virol. 2015 Nov;2(1):573-97. doi: 10.1146/annurev-virology-100114-055226. Epub 2015 Sep 2. PMID: 26958929; PMCID: PMC4785831.
2. Ugwu Okechukwu Paul-Chima and Alum Esther Ugo Emmanuel Ifeanyi Obeagu, D.C. Nwosu. Adverse Drug Reactions in HIV/AIDS Patients on Highly Active Antiretro Viral Therapy: A Review of Prevalence *newport international journal of scientific and experimental sciences (nijses)* 2023 *4(1), 43-47.* https://doi.org/10.59298/NIJSES/2023/10.6.1000
3. Esther Ugo Alum, OP Ugwu, Emmanuel Ifeanyi Obeagu, Michael Ben Okon. Curtailing HIV/AIDS spread: impact of religious leaders *Newport International Journal of Research in Medical Sciences NIJRMS 20213 3(2) 28-31*
4. Emmanuel Ifeanyi Obeagu, Stella Malot, Getrude Uzoma Obeagu, OP Ugwu. HIV resistance in patients with Sickle Cell Anaemia Newport International Journal of Scientific and Experimental Sciences 2023 3(2) 56-9
5. Esther Ugo Alum, Emmanuel Ifeanyi Obeagu, OP Ugwu, Patrick Maduabuchi Aja, Michael Ben Okon 2023. HIV infection and cardiovascular diseases: the obnoxious duos *Newport International Journal of Research in Medical Sciences (NIJRMS) 3(2)95-99*

6. Adeyinka O. Adepoju and Mariam O. Amusa Esther U. Alum, Emmanuel Ifeanyi Obeagu , Okechukwu P.C. Ugwu, Awotunde O. Samson Inclusion of nutritional counseling and mental health services in HIV/AIDS management A paradigm shift *Medicine® 2023.102(41) e35673*
7. Emmanuel Ifeanyi Obeagu, Getrude Uzoma Obeagu, Joseph Obiezu, Chukwujekwu Ezeonwumelu, Frances Ugonne Ogunnaya, Anthonia Onyinye Ngwoke, Obioma Raluchukwu Emeka-Obi, OP Ugwu. Hematologic Support in HIV Patients: Blood Transfusion Strategies and Immunological Considerations *Applied Sciences 2023 (NIJBAS)3(3)*
8. Michael Ben Okon and Daniel Ejim Uti Esther Ugo Alum, Okechukwu P. C. Ugwu , Emmanuel Ifeanyi Obeagu , Patrick Maduabuchi Aja Reducing HIV Infection Rate in Women: A Catalyst to reducing HIV Infection pervasiveness in Africa International *Journal of Innovative and Applied Research 2023. 11(10) 01-06.* http://dx.doi.org/10.58538/IJIAR/2048
9. Esther U. Alum and Puche Racheal Okwaja Emmanuel Ifeanyi Obeagu, Getrude Uzoma Obeagu, Edward Odogbu Odo, Matthew Chibunna Igwe, Okechukwu Paul-Chima Ugwu. Combatting Stigma: Essential Steps in Halting HIV Spread *International and applied Journal of Applied Sciences* 2024 *11(1) 22-29.* www.iaajournals.org
10. Iwasaki A, Medzhitov R. Control of adaptive immunity by the innate immune system. Nat Immunol. 2015 Apr;16(4):343-53. doi: 10.1038/ni.3123. PMID: 25789684; PMCID: PMC4507498.
11. Durantel D, Kusters I, Louis J, Manel N, Ottenhoff THM, Picot V, Saaadatian-Elahi M. Mechanisms behind TB, HBV, and HIV chronic infections. Infect Genet Evol. 2017 Nov;55:142-150. doi: 10.1016/j.meegid.2017.09.008. Epub 2017 Sep 13. PMID: 28919545.
12. Shin H, Wherry EJ. CD8 T cell dysfunction during chronic viral infection. CurrOpinImmunol. 2007 Aug;19(4):408-15. doi: 10.1016/j.coi.2007.06.004. Epub 2007 Jul 25. PMID: 17656078.
13. Gough M, Singh DK, Singh B, Kaushal D, Mehra S. System-wide identification of myeloid markers of TB disease and HIV-induced reactivation in the macaque model of Mtb infection and Mtb/SIV co-infection. Front Immunol. 2022 Oct 5;13:777733. doi: 10.3389/fimmu.2022.777733. PMID: 36275677; PMCID: PMC9583676.
14. DiNardo AR, Rajapakshe K, Nishiguchi T, Grimm SL, Mtetwa G, Dlamini Q, Kahari J, Mahapatra S, Kay A, Maphalala G, Mace EM, Makedonas G, Cirillo JD, Netea MG, van Crevel R, Coarfa C, Mandalakas AM. DNA hypermethylation during tuberculosis dampens host immune responsiveness. J Clin Invest. 2020 Jun 1;130(6):3113-3123. doi: 10.1172/JCI134622. PMID: 32125282; PMCID: PMC7260034.
15. Hossain MA, Liu G, Dai B, Si Y, Yang Q, Wazir J, Birnbaumer L, Yang Y. Reinvigorating exhausted $CD8^+$ cytotoxic T lymphocytes in the tumor microenvironment and current strategies in cancer immunotherapy. Med Res Rev. 2021 Jan;41(1):156-201. doi: 10.1002/med.21727. Epub 2020 Aug 25. PMID: 32844499.
16. McLane LM, Abdel-Hakeem MS, Wherry EJ. CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer. Annu Rev Immunol. 2019 Apr 26;37:457-495. doi: 10.1146/annurev-immunol-041015-055318. Epub 2019 Jan 24. PMID: 30676822.
17. Brenchley JM, Schacker TW, Ruff LE, Price DA, Taylor JH, Beilman GJ, Nguyen PL, Khoruts A, Larson M, Haase AT, Douek DC. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med. 2004 Sep 20;200(6):749-59. doi: 10.1084/jem.20040874. Epub 2004 Sep 13. PMID: 15365096; PMCID: PMC2211962.
18. Zheng P, Dou Y, Wang Q. Immune response and treatment targets of chronic hepatitis B virus infection: innate and adaptive immunity. Front Cell Infect Microbiol. 2023 Jun 22;13:1206720. doi: 10.3389/fcimb.2023.1206720. PMID: 37424786; PMCID: PMC10324618.
19. Bauer T, Jilg W. Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination. Vaccine. 2006 Jan 30;24(5):572-7. doi: 10.1016/j.vaccine.2005.08.058. Epub 2005 Sep 1. PMID: 16171909.
20. Hwang JK, Wang C, Du Z, Meyers RM, Kepler TB, Neuberg D, Kwong PD, Mascola JR, Joyce MG, Bonsignori M, Haynes BF, Yeap LS, Alt FW. Sequence intrinsic somatic mutation mechanisms contribute to affinity maturation of VRC01-class HIV-1 broadly neutralizing antibodies. Proc Natl AcadSci U S A. 2017 Aug 8;114(32):8614-8619. doi: 10.1073/pnas.1709203114. Epub 2017 Jul 26. PMID: 28747530; PMCID: PMC5559054.

21. Kocks C, Rajewsky K. Stepwise intraclonal maturation of antibody affinity through somatic hypermutation. Proc Natl AcadSci U S A. 1988 Nov;85(21):8206-10. doi: 10.1073/pnas.85.21.8206. PMID: 3263647; PMCID: PMC282396.
22. Charmoy M, Wyss T, Delorenzi M, Held W. PD-1+ Tcf1+ CD8+ T cells from established chronic infection can form memory while retaining a stableimprint of persistent antigen exposure. Cell Rep. 2021 Sep 7;36(10):109672. doi: 10.1016/j.celrep.2021.109672. Erratum in: Cell Rep. 2021 Nov 9;37(6):110010. doi: 10.1016/j.celrep.2021.110010. PMID: 34496259.
23. Ando M, Ito M, Srirat T, Kondo T, Yoshimura A. Memory T cell, exhaustion, and tumor immunity. Immunol Med. 2020 Mar;43(1):1-9. doi: 10.1080/25785826.2019.1698261. Epub 2019 Dec 10. PMID: 31822213.
24. Ogongo P, Porterfield JZ, Leslie A. Lung Tissue Resident Memory T-Cells in the Immune Response to *Mycobacterium tuberculosis*. Front Immunol. 2019 May 3;10:992. doi: 10.3389/fimmu.2019.00992. PMID: 31130965; PMCID: PMC6510113.
25. Draenert R, Le Gall S, Pfafferott KJ, Leslie AJ, Chetty P, Brander C, Holmes EC, Chang SC, Feeney ME, Addo MM, Ruiz L, Ramduth D, Jeena P, Altfeld M, Thomas S, Tang Y, Verrill CL, Dixon C, Prado JG, Kiepiela P, Martinez-Picado J, Walker BD, Goulder PJ. Immune selection for altered antigen processing leads to cytotoxic T lymphocyte escape in chronic HIV-1 infection. J Exp Med. 2004 Apr 5;199(7):905-15. doi: 10.1084/jem.20031982. PMID: 15067030; PMCID: PMC2211885.
26. Dyck L, Mills KHG. Immune checkpoints and their inhibition in cancer and infectious diseases. Eur J Immunol. 2017 May;47(5):765-779. doi: 10.1002/eji.201646875. Epub 2017 Apr 24. PMID: 28393361.
27. Marcocci ME, Napoletani G, Protto V, Kolesova O, Piacentini R, Li Puma DD, Lomonte P, Grassi C, Palamara AT, De Chiara G. Herpes Simplex Virus-1 in the Brain: The Dark Side of a Sneaky Infection. Trends Microbiol. 2020 Oct;28(10):808-820. doi: 10.1016/j.tim.2020.03.003. Epub 2020 May 5. PMID: 32386801.
28. Marcocci ME, Napoletani G, Protto V, Kolesova O, Piacentini R, Li Puma DD, Lomonte P, Grassi C, Palamara AT, De Chiara G. Herpes Simplex Virus-1 in the Brain: The Dark Side of a Sneaky Infection. Trends Microbiol. 2020 Oct;28(10):808-820. doi: 10.1016/j.tim.2020.03.003. Epub 2020 May 5. PMID: 32386801.
29. Hoffmann M, Pantazis N, Martin GE, Hickling S, Hurst J, Meyerowitz J, Willberg CB, Robinson N, Brown H, Fisher M, Kinloch S, Babiker A, Weber J, Nwokolo N, Fox J, Fidler S, Phillips R, Frater J; SPARTAC and CHERUB Investigators. Exhaustion of Activated CD8 T Cells Predicts Disease Progression in Primary HIV-1 Infection. PLoSPathog. 2016 Jul 14;12(7):e1005661. doi: 10.1371/journal.ppat.1005661. PMID: 27415828; PMCID: PMC4945085.
30. Kemming J, Thimme R, Neumann-Haefelin C. Adaptive Immune Response against Hepatitis C Virus. Int J Mol Sci. 2020 Aug 6;21(16):5644. doi: 10.3390/ijms21165644. PMID: 32781731; PMCID: PMC7460648.
31. Horzum U, Yanik H, Taskiran EZ, Esendagli G. Effector Th1 cells under PD-1 and CTLA-4 checkpoint blockade abrogate the upregulation of multiple inhibitory receptors and by-pass exhaustion. Immunology. 2022 Dec;167(4):640-650. doi: 10.1111/imm.13560. Epub 2022 Aug 25. PMID: 36053975.
32. Kim MK, Lee A, Hwang YK, Kang CY, Ha SJ. Enhancing T Cell Immune Responses by B Cell-based Therapeutic Vaccine Against Chronic Virus Infection. Immune Netw. 2014 Aug;14(4):207-18. doi: 10.4110/in.2014.14.4.207. Epub 2014 Aug 22. PMID: 25177253; PMCID: PMC4148491.
33. Fung S, Choi HSJ, Gehring A, Janssen HLA. Getting to HBV cure: The promising paths forward. Hepatology. 2022 Jul;76(1):233-250. doi: 10.1002/hep.32314. Epub 2022 Feb 16. PMID: 34990029.
34. Shinahara W, Takahashi E, Sawabuchi T, Arai M, Hirotsu N, Takasaki Y, Shindo S, Shibao K, Yokoyama T, Nishikawa K, Mino M, Iwaya M, Yamashita Y, Suzuki S, Mizuno D, Kido H. Immunomodulator clarithromycin enhances mucosal and systemic immune responses and reduces re-infection rate in pediatric patients with influenza treated with antiviral neuraminidase inhibitors: a retrospective analysis. PLoS One. 2013 Jul 17;8(7):e70060. doi: 10.1371/journal.pone.0070060. Erratum in: PLoS One. 2014;9(7):e104573. PMID: 23875018; PMCID: PMC3714257.

CITE AS: Kungu Erisa (2025). Adaptive Immunity in Response to Chronic Infections: A Mini Review. EURASIAN EXPERIMENT JOURNAL OF PUBLIC HEALTH, 7(1):1-6